179 related articles for article (PubMed ID: 38241568)
1. The long-term efficacy and safety of apatinib are inferior to sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis.
Li D; Zhang C; Yang K; Ma Z; Ma L; Cheng C; Xu L; Wan S
Medicine (Baltimore); 2024 Jan; 103(3):e36865. PubMed ID: 38241568
[TBL] [Abstract][Full Text] [Related]
2. Comparing Safety and Efficacy of TACE + Apatinib in Combination with a PD-1 Inhibitor versus a Non-triple Therapy for Treating Advanced Primary Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
Pan D; Liu H; Qu P; Chen X; Ma X; Wang Y; Qin X; Han Z
J Gastrointestin Liver Dis; 2024 Mar; 33(1):85-93. PubMed ID: 38554419
[TBL] [Abstract][Full Text] [Related]
3. Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study.
Yin L; Liu KC; Lv WF; Lu D; Tan YL; Wang GX; Dai JY; Zhu XH; Jiang B
Cancer Imaging; 2023 May; 23(1):52. PubMed ID: 37254146
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sorafenib combined with TACE in the treatment of advanced hepatocellular carcinoma: A meta-analysis.
Li D; Pang Y; Xu L; Xu X
J BUON; 2021; 26(4):1355-1364. PubMed ID: 34564992
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) plus apatinib versus DEB-TACE alone in treating huge hepatocellular carcinoma patients.
Li N; Chen J
Ir J Med Sci; 2022 Dec; 191(6):2611-2617. PubMed ID: 35083645
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of transarterial chemoembolization plus lenvatinib in the treatment of advanced hepatocellular carcinoma: A meta-analysis.
Li D; Liu S; Cheng C; Xu L; Zhao P
Medicine (Baltimore); 2023 Sep; 102(35):e34811. PubMed ID: 37657057
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of Apatinib combined with TACE in the treatment of hepatocellular carcinoma: a meta-analysis.
Gong A; Li X
World J Surg Oncol; 2022 Mar; 20(1):69. PubMed ID: 35246145
[TBL] [Abstract][Full Text] [Related]
8. Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis.
Zhang L; Hu P; Chen X; Bie P
PLoS One; 2014; 9(6):e100305. PubMed ID: 24945380
[TBL] [Abstract][Full Text] [Related]
9. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.
Zhang X; Wang K; Wang M; Yang G; Ye X; Wu M; Cheng S
Oncotarget; 2017 Apr; 8(17):29416-29427. PubMed ID: 28177886
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis.
Deng J; Liao Z; Gao J
Curr Oncol; 2023 Jan; 30(1):1243-1254. PubMed ID: 36661745
[TBL] [Abstract][Full Text] [Related]
11. The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study.
Yang Z; Chen G; Cui Y; Xiao G; Su T; Yu J; Zhang Z; Han Y; Yang K; Jin L
Cancer Biol Ther; 2019; 20(3):321-327. PubMed ID: 30332553
[TBL] [Abstract][Full Text] [Related]
12. Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study.
Qiu Z; Shen L; Jiang Y; Qiu J; Xu Z; Shi M; Yu Z; Ma Y; He W; Zheng Y; Li B; Wang G; Yuan Y
Ann Transl Med; 2021 Feb; 9(4):283. PubMed ID: 33708910
[TBL] [Abstract][Full Text] [Related]
13. Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study.
Jin ZC; Zhong BY; Chen JJ; Zhu HD; Sun JH; Yin GW; Ge NJ; Luo B; Ding WB; Li WH; Chen L; Wang YQ; Zhu XL; Yang WZ; Li HL; Teng GJ;
Eur Radiol; 2023 Dec; 33(12):8669-8681. PubMed ID: 37368105
[TBL] [Abstract][Full Text] [Related]
14. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of apatinib and transcatheter arterial chemoembolization as second-line therapy for advanced hepatocellular carcinoma: A retrospective cohort study.
Li T; Zhao J; Zhang S; Wang H; Sun L; Hu J
J Cancer Res Ther; 2023 Feb; 19(1):57-63. PubMed ID: 37006043
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Safety of Combination Therapy of Transarterial Chemoembolization and Apatinib for Unresectable Hepatocellular Carcinoma in the Chinese Population: A Meta-Analysis.
Wei Y; Liu J; Yan M; Zhao S; Long Y; Zhang W
Chemotherapy; 2019; 64(2):94-104. PubMed ID: 31569090
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study.
Li JX; Deng WX; Huang ST; Lin XF; Long MY; Zhang J; Su TS; Li LQ; Pang YD; Liang CF; Zhou HM; Lu HY; Liang SX; Xiang BD
Radiat Oncol; 2022 Jun; 17(1):106. PubMed ID: 35690773
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of apatinib in patients with sorafenib-transarterial chemoembolization refractory hepatocellular carcinoma: a retrospective study.
Cao Y; Ouyang T; Xiong F; Kan X; Chen L; Liang B; Zheng C
Hepatol Int; 2021 Oct; 15(5):1268-1277. PubMed ID: 34415515
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of apatinib versus sorafenib/placebo in first-line treatment for intermediate and advanced primary liver cancer: A systematic review and meta-analysis.
Peng D; Cai Y; Chen G; Hou M; Luo X; Dongzhi Z; Xie H; Liu Y
Front Pharmacol; 2023; 14():1101063. PubMed ID: 37153777
[No Abstract] [Full Text] [Related]
20. Transarterial chemoembolization (TACE) plus apatinib-combined therapy versus TACE alone in the treatment of intermediate to advanced hepatocellular carcinoma patients: A real-world study.
Wang H; Liu D; Wang C; Yu S; Jin G; Wang C; Zhang B; Zhang D; Shao D
Clin Res Hepatol Gastroenterol; 2022; 46(6):101869. PubMed ID: 35108656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]